# BPC-157 vs ARA-290: How They Differ | PepVault

Source: https://pepvault.app/peptides/compare/bpc-157-vs-ara-290

Last updated: 2026-10-08

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Library](https://pepvault.app/peptides) [Comparisons](https://pepvault.app/peptides/compare) BPC-157 vs ARA-290

Compared side by side

# BPC-157 vs ARA-290: how they differ

Reviewed October 2026 [How we check the library](https://pepvault.app/about#library) [Published by PepVault](https://pepvault.app/guides/how-we-research)

## The short answer

BPC-157 is a peptide derived from a protective protein in human gastric juice that, in animal studies, speeds the repair of tendons, ligaments, muscle and gut lining. ARA-290 is 11 amino acids copied from erythropoietin (EPO) that reach its tissue-repair receptor without raising red cells, and its four small randomized phase 2 trials measured nerve symptoms. BPC-157 is taken once or twice daily, commonly for 4–12 weeks; ARA-290’s trials gave it daily for 28 days or 12 weeks.

## Side by side

| Compared | [BPC-157](https://pepvault.app/peptides/bpc-157) | [ARA-290](https://pepvault.app/peptides/ara-290) |
| --- | --- | --- |
| Category | Healing & recovery | Healing & recovery |
| Also known as | Body Protection Compound 157, BPC157 | Cibinetide, ARA290, pHBSP, Helix B surface peptide, HBSP |
| What it is | A peptide derived from a protective protein in your stomach. | Eleven amino acids copied from the water-facing side of one helix in erythropoietin, the hormone that drives red-cell production — residues that sit side by side on that face, strung into a new chain rather than a stretch cut out of the hormone. |
| How it works | Synthetic pentadecapeptide derived from a protein in human gastric juice. In animal studies it promotes angiogenesis, speeds tendon, ligament and muscle healing, modulates dopamine and serotonin systems, and protects the gut lining. | An 11-amino-acid peptide copied from the water-facing side of helix B in erythropoietin (EPO). It binds the innate repair receptor — the EPO receptor paired with CD131, the beta common receptor — rather than the EPO receptor pair that drives red-cell production, so in lab and animal work it carries EPO's tissue-protective, anti-inflammatory signal without raising red cells. In rats with an injured nerve it reduced allodynia for weeks and damped the spinal microglia response. In people, four small randomized phase 2 trials measured nerve-symptom scores and corneal nerve-fiber density. |
| Commonly reported | Faster recovery from tendon and ligament injuries, and a calmer gut. It's one of the most widely used peptides in the community; the human studies so far are three small uncontrolled pilots. | Burning and tingling settling over the first one to two weeks, often with nothing to feel for a while first; one user who ran it for a pinched nerve noticed no change. Four small randomized trials exist and no approval. |
| Studied range | Research range: 200–500 mcg. Studied in research — not a recommendation. | Research range: 1–4 mg, starting dose 1 mg. Studied in research — not a recommendation. |
| How often | Once or twice daily | Daily |
| Half-life | ~4–6 hours (community estimate for SubQ; not measured in people: in rats and dogs it cleared in under 30 minutes) | ~20 minutes (measured in healthy volunteers after a SubQ dose; about 2 minutes after IV, and its developers argue a brief exposure is enough because the receptor acts as a switch) |
| Route | SubQ injection, IM injection, Oral (less studied) | SubQ injection |
| Typical run | Typically 4–12 weeks. Many run until injury resolves then stop. Some run indefinitely at lower doses. Opinions vary widely. | The published daily courses ran 28 days (three trials) and 12 weeks (the eye study). Community runs commonly last about four weeks and are repeated later. In the trial that followed people longest, the symptom improvement was still measurable 12 weeks after the last dose, and nine months after; nothing beyond 12 weeks of daily dosing has been studied. |
| Evidence | Emerging: primarily preclinical / limited human data | Moderate: animal studies + some human data |
| Common side effects | Nausea (rare), injection site irritation, vivid dreams, dizziness | Injection site reaction, headache, light-headedness, fatigue, nausea |

Typical run: Community practice — opinions vary. Not a clinical recommendation.

<!--promo-->

PepVault for iPhone

## Taking BPC-157 or ARA-290? Log it in PepVault

Each dose, each vial and your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

### BPC-157

- Day 1–7 Week one: early hints, for some
- Day 7–14 Pain often starts to ease
- Day 14–21 Pain often eases by week three
- Day 21–28 Many report a calmer gut
- Day 28–42 The slower part of repair
- Day 42–56 Six weeks in: taking stock
- Day 84+ Past week 12, the data runs thin

[Every card for BPC-157, with its sources](https://pepvault.app/peptides/bpc-157#weeks)

### ARA-290

- Day 1–14 The first two weeks: for some, the burning eases
- Day 14–28 Four weeks is where the trials looked
- Day 28–56 What happened after the dosing stopped
- Day 56–120 Past the trials' window

[Every card for ARA-290, with its sources](https://pepvault.app/peptides/ara-290#weeks)

## Together or one or the other

BPC-157 and ARA-290 are a common stack: ARA-290 lists BPC-157 among its common stacks.

Community · ARA-290

### Different jobs: the nerve and the tissue

A pairing the community reaches for when an injury hurts in a nerve way as well as a structural way. The split is honest: ARA-290's human data is about nerve symptoms and nerve-fiber counts, while BPC-157 and TB-500 rest on animal work about blood supply and repair cells moving in. Nothing has tested them together.

## With this comparison

### BPC-157

- [BPC-157: the full reference](https://pepvault.app/peptides/bpc-157)
- [BPC-157 dose guide](https://pepvault.app/lab/dosage/bpc-157)

### ARA-290

- [ARA-290: the full reference](https://pepvault.app/peptides/ara-290)
- [ARA-290 dose guide](https://pepvault.app/lab/dosage/ara-290)

### Mixing charts

- [BPC-157 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/bpc-157-5mg)
- [BPC-157 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/bpc-157-10mg)
- [ARA-290 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/ara-290-10mg)

### Studies

- [BPC-157: 10 of 12 women reported full interstitial cystitis relief](https://pepvault.app/research/bpc-157-lee-2024)
- [BPC-157: 14 of 16 reported knee pain relief in a chart review](https://pepvault.app/research/bpc-157-lee-2021)
- [BPC-157 closed duodenocolic fistulas in rats](https://pepvault.app/research/bpc-157-vukusic-2024)
- [All 6 studies](https://pepvault.app/research#bpc-157)
- [ARA-290: more corneal nerve fibers at 28 days in sarcoidosis, 4 mg arm](https://pepvault.app/research/ara-290-culver-2017)
- [ARA-290 eased neuropathic symptoms in sarcoidosis nerve fiber loss](https://pepvault.app/research/ara-290-dahan-2013)
- [ARA-290 improved small fiber neuropathy symptoms in sarcoidosis](https://pepvault.app/research/ara-290-heij-2012)
- [All 4 studies](https://pepvault.app/research#ara-290)

### Compared with

- [Retatrutide vs BPC-157](https://pepvault.app/peptides/compare/retatrutide-vs-bpc-157)
- [Semaglutide vs BPC-157](https://pepvault.app/peptides/compare/semaglutide-vs-bpc-157)
- [BPC-157 vs TB-500](https://pepvault.app/peptides/compare/bpc-157-vs-tb-500)
- [KPV vs BPC-157](https://pepvault.app/peptides/compare/kpv-vs-bpc-157)
- [GHK-Cu vs BPC-157](https://pepvault.app/peptides/compare/ghk-cu-vs-bpc-157)
- [BPC-157 vs Thymosin Beta-4](https://pepvault.app/peptides/compare/bpc-157-vs-thymosin-beta-4)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Amino acid](https://pepvault.app/glossary/amino-acid)
- [Subcutaneous (SubQ)](https://pepvault.app/glossary/subcutaneous)
- [Intramuscular (IM)](https://pepvault.app/glossary/intramuscular)
- [Half-life](https://pepvault.app/glossary/half-life)
- [Stack](https://pepvault.app/glossary/stack)

## Questions people ask

### How long do BPC-157 and ARA-290 last?

The half-life of BPC-157 is ~4–6 hours (community estimate for SubQ; not measured in people: in rats and dogs it cleared in under 30 minutes). The half-life of ARA-290 is ~20 minutes (measured in healthy volunteers after a SubQ dose; about 2 minutes after IV, and its developers argue a brief exposure is enough because the receptor acts as a switch).

### How often are BPC-157 and ARA-290 taken?

BPC-157: once or twice daily. Routes: SubQ injection, IM injection, oral (less studied). ARA-290: daily. Route: SubQ injection.

### How are BPC-157 and ARA-290 dosed in research?

The research range for BPC-157 is 200–500 mcg. The research range for ARA-290 is 1–4 mg, with a 1 mg starting dose. Studied in research — not a recommendation.

### What are the common side effects of BPC-157 and ARA-290?

For BPC-157, the library lists: nausea (rare), injection site irritation, vivid dreams, dizziness. For ARA-290: injection site reaction, headache, light-headedness, fatigue, nausea.

### Are BPC-157 and ARA-290 taken together?

BPC-157 and ARA-290 are a common stack: ARA-290 lists BPC-157 among its common stacks. A pairing the community reaches for when an injury hurts in a nerve way as well as a structural way. The split is honest: ARA-290's human data is about nerve symptoms and nerve-fiber counts, while BPC-157 and TB-500 rest on animal work about blood supply and repair cells moving in. Nothing has tested them together.

## Each one in full

- [BPC-157: dosage, half-life & reference guide](https://pepvault.app/peptides/bpc-157)
- [ARA-290: dosage, half-life & reference guide](https://pepvault.app/peptides/ara-290)
- [BPC-157 dose guide](https://pepvault.app/lab/dosage/bpc-157)
- [ARA-290 dose guide](https://pepvault.app/lab/dosage/ara-290)

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-next&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking BPC-157 or ARA-290? Log it in PepVault

Each dose, each vial and your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking BPC-157 or ARA-290? Log it in PepVault

Each dose, each vial and your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this comparison

### BPC-157

- [BPC-157: the full reference](https://pepvault.app/peptides/bpc-157)
- [BPC-157 dose guide](https://pepvault.app/lab/dosage/bpc-157)

### ARA-290

- [ARA-290: the full reference](https://pepvault.app/peptides/ara-290)
- [ARA-290 dose guide](https://pepvault.app/lab/dosage/ara-290)

### Mixing charts

- [BPC-157 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/bpc-157-5mg)
- [BPC-157 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/bpc-157-10mg)
- [ARA-290 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/ara-290-10mg)

### Studies

- [BPC-157: 10 of 12 women reported full interstitial cystitis relief](https://pepvault.app/research/bpc-157-lee-2024)
- [BPC-157: 14 of 16 reported knee pain relief in a chart review](https://pepvault.app/research/bpc-157-lee-2021)
- [BPC-157 closed duodenocolic fistulas in rats](https://pepvault.app/research/bpc-157-vukusic-2024)
- [All 6 studies](https://pepvault.app/research#bpc-157)
- [ARA-290: more corneal nerve fibers at 28 days in sarcoidosis, 4 mg arm](https://pepvault.app/research/ara-290-culver-2017)
- [ARA-290 eased neuropathic symptoms in sarcoidosis nerve fiber loss](https://pepvault.app/research/ara-290-dahan-2013)
- [ARA-290 improved small fiber neuropathy symptoms in sarcoidosis](https://pepvault.app/research/ara-290-heij-2012)
- [All 4 studies](https://pepvault.app/research#ara-290)

### Compared with

- [Retatrutide vs BPC-157](https://pepvault.app/peptides/compare/retatrutide-vs-bpc-157)
- [Semaglutide vs BPC-157](https://pepvault.app/peptides/compare/semaglutide-vs-bpc-157)
- [BPC-157 vs TB-500](https://pepvault.app/peptides/compare/bpc-157-vs-tb-500)
- [KPV vs BPC-157](https://pepvault.app/peptides/compare/kpv-vs-bpc-157)
- [GHK-Cu vs BPC-157](https://pepvault.app/peptides/compare/ghk-cu-vs-bpc-157)
- [BPC-157 vs Thymosin Beta-4](https://pepvault.app/peptides/compare/bpc-157-vs-thymosin-beta-4)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Amino acid](https://pepvault.app/glossary/amino-acid)
- [Subcutaneous (SubQ)](https://pepvault.app/glossary/subcutaneous)
- [Intramuscular (IM)](https://pepvault.app/glossary/intramuscular)
- [Half-life](https://pepvault.app/glossary/half-life)
- [Stack](https://pepvault.app/glossary/stack)

<!--promo-->

PepVault for iPhone

## Taking BPC-157 or ARA-290? Log it in PepVault

Each dose, each vial and your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## More comparisons

- [All peptide comparisons](https://pepvault.app/peptides/compare)
- [Retatrutide vs BPC-157](https://pepvault.app/peptides/compare/retatrutide-vs-bpc-157)
- [Semaglutide vs BPC-157](https://pepvault.app/peptides/compare/semaglutide-vs-bpc-157)
- [BPC-157 vs TB-500](https://pepvault.app/peptides/compare/bpc-157-vs-tb-500)
- [KPV vs BPC-157](https://pepvault.app/peptides/compare/kpv-vs-bpc-157)
- [GHK-Cu vs BPC-157](https://pepvault.app/peptides/compare/ghk-cu-vs-bpc-157)
- [BPC-157 vs Thymosin Beta-4](https://pepvault.app/peptides/compare/bpc-157-vs-thymosin-beta-4)

## The library

- [The peptide reference library](https://pepvault.app/peptides)
- [Healing & recovery peptides](https://pepvault.app/peptides#healing)

## Free tools

- [The Dose Guide](https://pepvault.app/lab/dosage)
- [Half-life & active level](https://pepvault.app/tools/peptide-half-life-calculator)
- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
